143 related articles for article (PubMed ID: 6203662)
21. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
22. Vincristine, adriamycin, and mitomycin (VAM) therapy for previously treated breast cancer. A preliminary report.
Oster MW; Park Y
Cancer; 1983 Jan; 51(2):203-5. PubMed ID: 6821812
[TBL] [Abstract][Full Text] [Related]
23. Myelosuppression after methotrexate, mitozantrone, and mitomycin C for treatment of advanced breast cancer.
Marks A; Goodman A; Dougherty S; Ashford R
Lancet; 1987 Apr; 1(8538):915. PubMed ID: 2882308
[No Abstract] [Full Text] [Related]
24. Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer.
Bishop JF; Raghavan D; Woods R; Coates A; Burns I; Jeal PN; Hillcoat BL; Tattersall MN
Cancer Treat Rep; 1987 Feb; 71(2):191-3. PubMed ID: 2433037
[TBL] [Abstract][Full Text] [Related]
25. Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study.
Muhonen T; Jantunen I; Pertovaara H; Voutilainen L; Maiche A; Blomqvist C; Pyrhönen S; Kellokumpu-Lehtinen P
Am J Clin Oncol; 1996 Jun; 19(3):232-4. PubMed ID: 8638531
[TBL] [Abstract][Full Text] [Related]
26. A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer.
Powles TJ; Jones AL; Judson IR; Hardy JR; Ashley SE
Br J Cancer; 1991 Aug; 64(2):406-10. PubMed ID: 1892775
[TBL] [Abstract][Full Text] [Related]
27. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
Antman K; Eder JP; Elias A; Shea T; Peters WP; Andersen J; Schryber S; Henner WD; Finberg R; Wilmore D
Cancer Treat Rep; 1987 Feb; 71(2):119-25. PubMed ID: 3542208
[TBL] [Abstract][Full Text] [Related]
28. Methotrexate and mitomycin for patients with metastatic transitional cell carcinoma of the urinary tract.
Tannock IF
Cancer Treat Rep; 1983 May; 67(5):503-4. PubMed ID: 6406061
[TBL] [Abstract][Full Text] [Related]
29. Mitomycin C in metastatic breast cancer resistant to hormone therapy and conventional chemotherapy.
De Lena M; Jirillo A; Brambilla C; Villa S
Tumori; 1980 Aug; 66(4):481-87. PubMed ID: 7414712
[TBL] [Abstract][Full Text] [Related]
30. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
31. Etoposide and mitomycin-C in pretreated metastatic breast cancer.
Menichetti ET; Silva RR; Tummarello D; Miseria S; Torresi U; Cellerino R
Tumori; 1989 Oct; 75(5):473-4. PubMed ID: 2513674
[TBL] [Abstract][Full Text] [Related]
32. MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer.
Hsu C; Yeh KH; Hong RL; Yang CH; Lin MT; Chen YC; Cheng AL
J Formos Med Assoc; 1997 Mar; 96(3):185-8. PubMed ID: 9080756
[TBL] [Abstract][Full Text] [Related]
33. Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer.
Patrone F; Ballestrero A; Ferrando F; Brema F; Moraglio L; Valbonesi M; Basta P; Ghio R; Gobbi M; Sessarego M
J Clin Oncol; 1995 Apr; 13(4):840-6. PubMed ID: 7707109
[TBL] [Abstract][Full Text] [Related]
34. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
Bitran JD; Samuels B; Klein L; Hanauer S; Johnson L; Martinec J; Harris E; Kempler J; White W
Bone Marrow Transplant; 1996 Feb; 17(2):157-62. PubMed ID: 8640160
[TBL] [Abstract][Full Text] [Related]
35. A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast.
Gregory RK; Powles TJ; Chang JC; Ashley S
Eur J Cancer; 1997 Nov; 33(13):2194-7. PubMed ID: 9470805
[TBL] [Abstract][Full Text] [Related]
36. Mitomycin C and 5-fluorouracil as second choice treatment in advanced breast cancer patients.
Ardizzoni A; Pronzato P; Conte PF; Rosso R
Chemioterapia; 1984 Apr; 3(2):83-5. PubMed ID: 6442624
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma.
Legha SS; Buzdar AU; Hortobagyi GN; DiStefano A; Wiseman CL; Yap HY; Blumenschein GR; Bodey GP
Cancer Treat Rep; 1979; 63(11-12):2053-6. PubMed ID: 118805
[TBL] [Abstract][Full Text] [Related]
38. Mitomycin and methotrexate: negative experience in untreated colorectal carcinoma.
Wernz JC; Kao AK; Muggia FM; Asbury RF
Cancer Treat Rep; 1985 Feb; 69(2):223-4. PubMed ID: 3918793
[No Abstract] [Full Text] [Related]
39. Phase I study of mitozantrone, methotrexate and mitomycin with granulocyte colony-stimulating factor (filgrastim) in patients with advanced breast cancer.
O'Brien ME; Nicolson M; Montes A; Tidy A; Ashley S; Powles TJ
Br J Cancer; 1994 Nov; 70(5):980-3. PubMed ID: 7524607
[TBL] [Abstract][Full Text] [Related]
40. Adriamycin and mitomycin C as initial chemotherapy for advanced breast cancer.
Amiel SA; Stewart JF; Earl HM; Knight RK; Rubens RD
Eur J Cancer Clin Oncol; 1984 May; 20(5):631-4. PubMed ID: 6428893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
